[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555051":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":92,"collaborators":94,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":32,"enrollmentInfo":108,"targetDuration":32,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immediate Long-Acting Injectable Treatment Group","EXPERIMENTAL","Immediate switch to long-acting injectable antiretrovirals on enrollment",[13],"Drug: cabotegravir\u002Frilpivirine (600mg\u002F 900mg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Delayed Long-Acting Injectable Treatment Group","ACTIVE_COMPARATOR","Keep on standard all-oral antiretrovirals on enrollment for 24 weeks, then switch to long-acting injectable antiretrovirals",[19],"Drug: Antiretroviral Combinations",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","cabotegravir\u002Frilpivirine (600mg\u002F 900mg)","Immediate switch from oral antiretroviral to long-acting injectables",[9],[27],"Cabenuva",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Antiretroviral Combinations","Standard all-oral antiretroviral combinations",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Nan-Yu Chen, MD, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","+886 3 3281200","8450","nanyuchen@cgmh.org.tw",[44,60,71,84],{"facility":45,"status":46,"city":47,"state":32,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Chang Gung Memorial Hospital, Keelung","RECRUITING","Keelung","204","Taiwan","TW",{"type":52,"coordinates":53},"Point",[54,55],121.74094,25.13089,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":32,"phoneExt":32,"email":42},"Nan-Yu Chen",{"facility":61,"status":46,"city":62,"state":32,"zip":63,"country":49,"countryCode":50,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Chang Gung Memorial Hospital, Taipei","Taipei","105",{"type":52,"coordinates":65},[66,67],121.52639,25.05306,{"lat":67,"lon":66},[70],{"name":59,"role":39,"phone":32,"phoneExt":32,"email":42},{"facility":72,"status":46,"city":73,"state":32,"zip":74,"country":49,"countryCode":50,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Taoyuan General Hospital, Ministry of Health and Welfare","Taoyuan","330",{"type":52,"coordinates":76},[77,78],121.29696,24.99368,{"lat":78,"lon":77},[81],{"name":82,"role":39,"phone":32,"phoneExt":32,"email":83},"Chien-Yu Cheng, MD, PhD","s841060@gm.ym.edu.tw",{"facility":85,"status":46,"city":73,"state":32,"zip":86,"country":49,"countryCode":50,"cosmosGeoPoint":87,"geoPoint":89,"contacts":90},"Chang Gung Memorial Hospital, Linkou","333",{"type":52,"coordinates":88},[77,78],{"lat":78,"lon":77},[91],{"name":59,"role":39,"phone":40,"phoneExt":41,"email":42},{"type":93,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[95],{"name":96,"class":97},"Taoyuan General Hospital","OTHER_GOV","100555051","phase-3-outcomes-of-the-plhiv-with-suboptimal-viral-suppression-to-injectable-long-acting-antiretrovirals-100555051",false,"NCT06507059","Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","A Phase 3 Study Comparing Clinical Outcomes in People Living With HIV (PLHIV) With Suboptimal Adherence Treated With Injectable Long-acting Antiretrovirals Versus Oral Antiretrovirals","SUPLA","Inclusion Criteria:\n\n* Willing to sign the written informed consent form for male and female participants aged 18 and above.\n* At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months.\n* Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies\u002FmL.\n* Body weight ≥ 35Kg.\n* Willing to maintain contact with the research team throughout the study (provide accurate and reachable phone numbers, social accounts like Line, or reliable contact information of family or friends).\n* Willing to receive gluteal (buttocks) drug injections.\n* Willing to transition back to oral medication or follow the recommended treatment prescription according to the then-current national treatment guidelines after discontinuation of long-acting injectable drugs.\n\nExclusion Criteria:\n\n* For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening.\n* Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine.\n* Unable to commit to maintaining contact with the research team throughout the study.\n* Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers.\n* Individuals with buttock fillers.\n* Women who are planning to become pregnant, pregnant, or currently breastfeeding.","ALL","18 Years",{"count":109,"type":110},40,"ESTIMATED","INTERVENTIONAL",[113],"PHASE3","This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.",[116,117],"HIV-1-infection","Non-Adherence, Medication",[119],"HIV-1, non-adherence","2024-08-21",{"date":122,"type":123},"2024-08-23","ACTUAL",{"date":125,"type":123},"2024-07-19",{"date":127,"type":110},"2026-12-31",{"name":5,"class":6},4]